Papa Murphy's Holdings (FRSH) PT Lowered to $5 at Jefferies; Remains Sidelined
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 05/10: (SGMO) (RELY) (PEGA) Higher; (NH) (SNAP) (MNKD) Lower (more...)
May 10, 2017 6:25 PM EDTToday's After-Hours Movers
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) 39% HIGHER; Sangamo and Pfizer Inc. (NYSE: PFE) today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
NantHealth (NASDAQ: NH) 24% LOWER; reported Q1 EPS of ($0.24), $0.04 worse than the analyst estimate of ($0.20). Revenue for the quarter... More
Papa Murphy's (FRSH) Misses Q1 EPS by 25c, Miss on Revenues; Increases FY17 Cash FLlow Outlook
May 10, 2017 4:12 PM EDTPapa Murphy's (NASDAQ: FRSH) reported Q1 EPS of ($0.32), $0.25 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $32 million versus the consensus estimate of $35.21 million.
... More
